SK bioscienceLtd 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jae-Yong Ahn

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3.7yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.9yrs

최근 관리 업데이트

Recent updates

Is SK bioscienceLtd (KRX:302440) A Risky Investment?

Jul 11

SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 23

CEO

Jae-Yong Ahn (57 yo)

3.7yrs

테뉴어

Mr. Jae-Yong Ahn is the Chief Executive Officer and President of SK bioscience Co.,Ltd since March 2021 and served as its Chairman since March 2021. He serves as Executive Officer and Director of VAX Busi...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jae-Yong Ahn	CEO, President & Director	no data	데이터 없음	0.056% ₩ 2.4b
Hoon Kim	Executive Director	3.7yrs	데이터 없음	0.056% ₩ 2.4b
Kwon Ik-Hwan	Independent Chairman of the Board	3.7yrs	데이터 없음	데이터 없음
Moon Chang-Jin	Independent Outside Director	4.1yrs	데이터 없음	데이터 없음
Choi Jeong-Wook	Independent Outside Director	4.1yrs	데이터 없음	데이터 없음

3.9yrs

평균 재임 기간

경험이 풍부한 이사회: A302440 의 이사회는 경험(평균 재직 기간 3.9 년)으로 간주됩니다.

SK bioscienceLtd 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Insufficient new directors

SK bioscience Co.,Ltd., Annual General Meeting, Mar 25, 2024

High number of new and inexperienced directors

SK bioscience Announces Executive Appointments

Less than half of directors are independent

Recent updates

Consensus revenue estimates increase by 16%

New minor risk - Shareholder dilution

SK bioscience Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024

SK bioscience Co.,Ltd. (KOSE:A302440) agreed to acquire an unknown stake in Fina Biosolutions, LLC for $3 million.

SK bioscience Co.,Ltd. (KOSE:A302440) agreed to acquire an unknown minority stake in Fina Biosolutions, LLC for $3 million.

SK bioscience Co.,Ltd. (KOSE:A302440) agreed to acquire an unknown minority stake in Fina Biosolutions, LLC for $3 million.

Consensus EPS estimates upgraded to ₩341 loss, revenue downgraded

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 10% to ₩51,667

Second quarter 2024 earnings released: ₩148 loss per share (vs ₩208 loss in 2Q 2023)

SK bioscience Co.,Ltd. to Report Q2, 2024 Results on Jul 31, 2024

Is SK bioscienceLtd (KRX:302440) A Risky Investment?

Consensus EPS estimates fall by 59%

Insufficient new directors

SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings released: EPS: ₩291 (vs ₩1,596 in FY 2022)

SK bioscience Co.,Ltd., Annual General Meeting, Mar 25, 2024

SK Bioscience Obtains Prequalification Certification from the World Health Organization

Consensus revenue estimates fall by 13%

Consensus EPS estimates fall by 12%, revenue upgraded

SK bioscience Co.,Ltd. to Report Q4, 2023 Results on Feb 01, 2024

Price target decreased by 7.5% to ₩56,714

SK bioscience Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Consensus revenue estimates increase by 15%

Investor sentiment improves as stock rises 17%

Consensus revenue estimates decrease by 17%

SK bioscience Co.,Ltd. to Report Q2, 2023 Results on Jul 28, 2023

Consensus estimates of losses per share improve by 59%

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Price target decreased by 8.2% to ₩59,875

Consensus revenue estimates decrease by 34%

Investor sentiment improves as stock rises 17%

Consensus EPS estimates fall by 12%, revenue upgraded

Consensus revenue estimates fall by 18%

Price target decreased by 13% to ₩75,545

SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs

SK bioscience Co.,Ltd. to Report Q4, 2022 Results on Feb 08, 2023

SK Bioscience Co.,Ltd. Receives Expanded Manufacturing and Marketing Approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid

SK Bioscience Receives Biologics License Application Approval of the Skyzoster™ from the National Pharmaceutical Regulatory Agency in Malaysia

High number of new and inexperienced directors

Price target decreased to ₩103,400

Price target decreased to ₩114,700

SK bioscience Announces Executive Appointments

SK bioscience Co.,Ltd. to Report Q3, 2022 Results on Oct 31, 2022

Price target decreased to ₩124,300

Consensus EPS estimates fall by 11%

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

SK bioscience Receives Post Approval Change Application Approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid™ (NVX-CoV2373) COVID-19 Vaccine

Consensus EPS estimates fall by 11%

Consensus revenue estimates fall by 11%

Price target decreased to ₩151,667

Consensus revenue estimates fall by 10%

Investor sentiment improved over the past week

Price target decreased to ₩167,222

Price target decreased to ₩167,222

Consensus EPS estimates fall by 12%

Investor sentiment deteriorated over the past week

Price target decreased to ₩192,250

Consensus EPS estimates fall by 17%

Price target decreased to ₩216,250

Less than half of directors are independent

Price target decreased to ₩225,714

Investor sentiment deteriorated over the past week

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

SK Bioscience and GSK Start Phase 3 Trial of Adjuvanted Covid-19 Vaccine Candidate

CEO